Cerebral venous sinus thrombosis (CVST) is a rare and potentially life-threatening cause of stroke. In the past few decades, the incidence and patient demographics have changed because of many factors, including the widespread use of oral contraceptives, improved detection of prothrombotic conditions, and advancement of imaging technology. The presentation of CVST is varied and can include ocular signs and symptoms. We present 2 cases of oral contraceptive–induced CVST in 18-year-old women, whose main presenting findings were ophthalmologic.
FischerCGoldsteinJEdlowJ. Cerebral venous sinus thrombosis in the emergency department: retrospective analysis of 17 cases and review of the literature. J Emerg Med. 2010;38:140-147.
2.
SébireGTabarkiBSaundersDE. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain. 2005;128(pt 3):477-489.
3.
GameiroJFerroJMCanhãoPStamJBarinagarrementeriaFLindgrenA; International Study on Cerebral Vein and Dural Sinus Thrombosis Investigators. Prognosis of cerebral vein thrombosis presenting as isolated headache: early vs. late diagnosis. Cephalalgia. 2012;32:407-412.
4.
NarayanDKaulSRavishankarK. Risk factors, clinical profile, and long-term outcome of 428 patients of cerebral sinus venous thrombosis: insights from Nizam’s Institute Venous Stroke Registry, Hyderabad (India). Neurol India. 2012;60:154-159.
StamJ. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352:1791-1798.
7.
BuccinoGScodittiUPiniMTagliaferriARManottiCManciaD. Low-oestrogen oral contraceptives as a major risk factor for cerebral venous and sinus thrombosis: evidence from a clinical series. Ital J Neurol Sci. 1999;20:231-235.
8.
de BruijnSFStamJKoopmanMMVandenbrouckeJP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ. 1998;316:589-592.
9.
van Hylckama VliegAHelmerhorstFMVandenbrouckeJPDoggenCJRosendaalFR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.
10.
HeringsRMUrquhartJLeufkensHG. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999;354:127-128.
RosingJTansGNicolaesGA. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233-238.
13.
FarleyTMMeirikOChangCLPoulterNR. Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health. 1998;52:775-785.
14.
MartinelliISacchiELandiGTaioliEDucaFMannucciPM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oralcontraceptives. N Engl J Med. 1998;338:1793-1797.
15.
SmithKJMonsefBSRagniMV. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thromb Haemost. 2008;100:447-452.
16.
NicastroNSchniderALeemannB. Iron-deficiency anemia as a rare cause of cerebral venous thrombosis and pulmonary embolism. Case Rep Med. 2012;2012:497814.
17.
WangDFangBWeiS. Analysis of clinical features of ocular presentation in cranial venous sinus thrombosis. Eur J Med Res. 2011;16:324-327.
18.
CoutinhoJMFerroJMCanhãoP. Cerebral venous and sinus thrombosis in women. Stroke. 2009;40:2356-2361.
